Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 302Parkinson Disease 4, Autosomal Dominant Lewy Body 180Melanoma 166Neoplasms 133Squamous Cell Carcinoma of Head and Neck 126Neoplasm Metastasis 98Colorectal Neoplasms 96Carcinoma, Renal Cell 80Triple Negative Breast Neoplasms 75Head and Neck Neoplasms 72Stomach Neoplasms 70Lung Neoplasms 68Breast Neoplasms 60Ovarian Neoplasms 56Carcinoma, Transitional Cell 51Uterine Cervical Neoplasms 44Endometrial Neoplasms 44Pancreatic Neoplasms 43Urinary Bladder Neoplasms 40Esophageal Neoplasms 40Carcinoma, Hepatocellular 37Small Cell Lung Carcinoma 30Cholangiocarcinoma 24Prostatic Neoplasms 22Carcinoma 22Lymphoma 20Carcinoma, Squamous Cell 20Recurrence 17Sarcoma 16Esophageal Squamous Cell Carcinoma 16

Interventions

pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Non Small Cell Lung Cancer Metastatic × pembrolizumab × Clear all
NCT05117242 2026-04-30

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Genmab

Phase 2 Active not recruiting
125 enrolled
Thoracic

Non Small Cell Lung Cancer Metastatic

NCT05668650 2024-07-16

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Laboratorio Elea Phoenix S.A.

Phase 3 Recruiting
174 enrolled
Thoracic

Non Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡